The Technical Analyst
CinCor Pharma, Inc. [CINC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
CinCor Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $29.06
America/New_York / 23 feb 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 271.79 mill |
| EPS: | -2.01 |
| P/E: | -14.46 |
| Earnings Date: | Nov 03, 2022 |
| SharesOutstanding: | 43.76 mill |
| Avg Daily Volume: | 0.626 mill |
| RATING 2023-03-03 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | n/a | n/a | ||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -14.46 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.46x |
| Company: PE -14.46 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 28.20 - 29.92 ( +/- 2.96%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-02-24 | 5am Partners Vi, Llc | Sell | 496 323 | Common Stock |
| 2023-02-24 | Healy James | Sell | 9 803 | Common Stock |
| 2022-11-28 | Healy James | Sell | 6 000 | Common Stock |
| 2023-02-24 | Healy James | Sell | 19 608 | Common Stock |
| 2023-02-24 | Healy James | Sell | 6 073 949 | Common Stock |
| INSIDER POWER |
|---|
| -68.53 |
| Last 98 transactions |
| Buy: 39 839 974 | Sell: 98 795 779 |
Forecast:
01:40 - $21.60
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $29.06 (0.00% ) |
| Volume | 0 mill |
| Avg. Vol. | 0.626 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CINC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CINC
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2023-01-09 22:55:00 - Press Release
Shareholder Alert: Weiss Law Investigates Cincor Pharma, Inc.
New york , jan. 9, 2023 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of cincor pharma, inc. ("cincor" or the "company") (nasdaq: cinc), in connection with the proposed acquisition of the company by astrazeneca plc (nasdaq: azn) via tender offer. under the terms of the merger agreement, the company's shareholders will receive $26.00 in cash for each share of cincor common stock owned, plus a non-tradable contingent value right ("cvr") of $10.00.
2022-11-22 18:44:00 - Press Release
Cincor Pharma To Present At Upcoming Piper Sandler And Evercore Isi Investor Conferences
Waltham, mass., nov. 22, 2022 (globe newswire) -- cincor pharma, inc. (nasdaq: cinc) today announced that company management will present at the following investor conferences in november:
2022-08-31 08:00:00 - Press Release
Cincor Pharma To Participate At Upcoming September Investor Conferences
Waltham, mass., aug. 31, 2022 (globe newswire) -- cincor pharma, inc. (nasdaq: cinc) today announced that company management will participate at the following investor conferences: citi's 17th annual biopharma conference taking place september 6 - 8, 2022 in boston, ma and morgan stanley's 20th annual healthcare conference, taking place september 12 - 13, 2022 in new york, ny.
2022-05-31 16:05:00 - Press Release
Cincor Pharma To Present At The Jefferies Healthcare Conference
Waltham, mass., may 31, 2022 (globe newswire) -- cincor pharma, inc. (nasdaq: cinc) today announced participation at the jefferies 2022 healthcare conference taking place june 8 - 10 in new york, new york. the cincor management team will give a corporate presentation on june 9, 2022, at 9 am edt.
2022-05-17 16:05:00 - Press Release
Cincor Pharma To Present At Upcoming Investor Conferences
Waltham, mass., may 17, 2022 (globe newswire) -- cincor pharma, inc. (nasdaq: cinc) today announced that management will present at the h.c. wainwright 2022 global investment conference taking place on may 23-26 virtually and in miami, florida, and at the ubs 2022 global healthcare conference taking place on may 23-25 in new york, new york.
Latest News
2023-02-13 09:23:59 - MarketBeat
There's a Lot to Love About Mineralys' Valentine's Day IPO
It has been less than a year since Mineralys Therapeutics (NASDAQ: MLYS) listed its IPO, but the activity has been quite hot, particularly since the top of the year. With 2.71 million in trading volume, there certainly appears to be a lot of interest in the budding clinical-stage biopharmaceutical company.
2023-01-09 10:42:44 - InvestorPlace
Why Is CinCor (CINC) Stock Up 138% Today?
CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has it agreeing to a tender offer of $26 per share for CINC stock.
2023-01-09 07:09:41 - Proactive Investors
AstraZeneca to acquire CinCor for US$1.8bn
AstraZeneca PLC (LSE:AZN) has announced it will acquire US-based biopharmaceutical firm CinCor for approximately US$1.8bn in an effort to boost its treatments of cardiorenal diseases. As part of the deal, AstraZeneca will also acquire CinCor's cash and marketable securities, valued at US$522mln late September.
2023-01-09 04:32:00 - Barrons
AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal
AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline
2023-01-09 02:16:33 - Reuters
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.
2022-12-13 22:55:50 - 24/7 Wall Street
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.
2022-11-29 13:32:11 - Zacks Investment Research
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
2022-11-28 08:52:23 - Market Watch
CinCor's hypertension drug misses primary endpoint in mid-stage study
Shares of CinCor Pharma Inc. CINC, +3.51% fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed to meet the primary endpoint in a Phase 2 clinical trial. CinCor said it still plans to meet with the Food and Drug Administration in January to discuss plans for its Phase 3 program for baxdrostat.
2022-11-22 18:44:00 - GlobeNewsWire
CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:
2022-11-16 21:21:59 - 24/7 Wall Street
These Are the 10 Best-Performing IPOs in 2022 Through October
The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.